Neuroinflammatory Triangle Presenting Novel Pharmacological Targets for Ischemic Brain Injury by Shaheryar, Zaib A. et al.

















This article was submitted to
Multiple Sclerosis
and Neuroimmunology,
a section of the journal
Frontiers in Immunology
Received: 28 July 2021
Accepted: 15 September 2021
Published: 07 October 2021
Citation:
Shaheryar ZA, Khan MA, Adnan CS,
Zaidi AA, Hänggi D and Muhammad S
(2021) Neuroinflammatory Triangle
Presenting Novel Pharmacological




published: 07 October 2021
doi: 10.3389/fimmu.2021.748663Neuroinflammatory Triangle
Presenting Novel Pharmacological
Targets for Ischemic Brain Injury
Zaib A. Shaheryar1,2, Mahtab A. Khan3, Ch. Sherjeel Adnan2, Awais Ali Zaidi2,4,
Daniel Hänggi6 and Sajjad Muhammad5,6*
1 Institute for Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Lübeck, Germany, 2 Faculty of
Pharmacy, University of Lahore, Lahore, Pakistan, 3 Faculty of Pharmacy, University of Central Punjab, Lahore, Pakistan,
4 Imran Idrees College of Pharmacy, Lahore, Pakistan, 5 Department of Neurosurgery, University of Helsinki and Helsinki
University Hospital, Helsinki, Finland, 6 Department of Neurosurgery, Faculty of Medicine and University Hospital Düsseldorf,
Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
Ischemic stroke is one of the leading causes of morbidity and mortality globally. Hundreds
of clinical trials have proven ineffective in bringing forth a definitive and effective treatment
for ischemic stroke, except a myopic class of thrombolytic drugs. That, too, has little to do
with treating long-term post-stroke disabilities. These studies proposed diverse options to
treat stroke, ranging from neurotropic interpolation to venting antioxidant activity, from
blocking specific receptors to obstructing functional capacity of ion channels, and more
recently the utilization of neuroprotective substances. However, state of the art knowledge
suggests that more pragmatic focus in finding effective therapeutic remedy for stroke
might be targeting intricate intracellular signaling pathways of the ‘neuroinflammatory
triangle’: ROS burst, inflammatory cytokines, and BBB disruption. Experimental evidence
reviewed here supports the notion that allowing neuroprotective mechanisms to advance,
while limiting neuroinflammatory cascades, will help confine post-stroke damage
and disabilities.
Keywords: neuroinflammation, blood brain barrier, cytokine, brain microvascular endothelial cell, reactive
oxidative speciesHIGHLIGHTS
This review article highlights important cellular and subcellular targets for stroke, and might aid the
scientific community in deeply understanding and targeting one or more these targets, to develop
clinical therapeutic interventions in stroke.INTRODUCTION
Stroke follows heart diseases and cancer as the highest global cause of mortality. It is the leading
cause of permanent disabilities (1). Stroke is generally classified into hemorrhagic and ischemic,
with the latter involved in about 85% of stroke accidents (2). Hemorrhagic stroke underscores the
rupture of intracranial aneurysm (ICA), dural arteriovenous fistula (dAVF), cerebral arteriovenousorg October 2021 | Volume 12 | Article 7486631
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hypertension, while ischemic stroke represents embolic or
thrombotic occlusion in a brain artery (3, 4). In either of these
cases, the repercussions are brain-tissue injury and functional
disabilities due to damage to the respective brain region (5). The
instant and primary damage to the brain cells are followed by
neuroinflammatory cascade entailing bursts of reactive oxygen
species (ROS), release of a variety of signaling cytokines, and
damage to the cerebral microvasculature, as well as disruption of
the blood-brain barrier (BBB) (6–9). These molecular
neuroinflammatory mechanisms potentiate damage to the
brain cells and influence the clinical outcome.
Neuroinflammation comprises of complex cellular and sub-
cellular mechanisms triggered in response to injury in brain cells
(10). The main driving factor for the carrying out of
neuroinflammation is the bid to root out the damaging stimulus,
however, once initiated it might become over activated, spreading
initially to the damaged brain regions and initiating a range of
intricate signaling pathways that advance the neuroinflammation to
the next level (11, 12). In acute phase, the damaged neuronal cells
and resident immune cells secrete inflammatory mediators
including cytokines, free radicals, and prostaglandins to signal
other inflammatory fragments (13). In response, neighboring glia
and microglia are activated which further secrete chemical
mediators to make arrangements for the disruption of the blood
brain barrier and invite immune cells from systemic circulation to
expand the scope of neuroinflammation (14). The ROS burst,
cytokines, related subcellular pathways, and disrupted BBB all
contribute to inflammation-mediated tissue damage (15). This
triangle of ROS, cytokines, and BBB, is the most simplified
concept in understanding how neuroinflammation advances brain
injuries, particularly after stroke.CYTOKINE-RELATED PATHWAYS IN THE
NEUROINFLAMMATORY TRIANGLE
Following ischemic stroke, damaged neurons, regional microglia,
and astrocytes become the repository of initial stimuli for
neuroinflammation. Microglial cells are a specialized
population of macrophages that are resident in the brain and
spinal cord (16). They do not inhabit a particular location, but
rather advance to different areas in order to clear the debris of
dead neurons, maintain tissue homeostasis, phagocytose
infiltrating pathogens or necrotic cells, release immune factors
that are either inflammatory or regulatory, and facilitate the
repair process in damaged parts of the brain provoked by
mediators released in the vicinity (17–21).
After the onset of ischemic stroke, it takes no longer than a few
minutes to initiate the neuroinflammatory cascade (10). As soon as
the microglial cells are activated, they not only change shape
(morphological transformation) and polarize into special
phenotypes, but also kickstart inflammatory signaling pathways (22).
Traditional approaches have classified activated brainmicroglia
into two key sub-populations: M1 and M2 (23). To which
phenotypic population they will switch to depends upon theFrontiers in Immunology | www.frontiersin.org 2nature and intensity of the stimuli (24, 25). M1 microglia are
referred to as “pro-inflammatory” cells as they aggravate neuronal
damage in ischemic brain regions along with disrupting the BBB to
varying extents (26, 27). The compromised BBB subsequently
allows infiltration of systemic leukocytes at the site of ischemic
insult, expending the inflammatory cascade and neuronal damage
(16). The reported pro-inflammatory mediators released and their
respective pathways are discussed under separate headings below.
Pro-Inflammatory Mediators Released by
M1 Phenotype of Microglial Cells
Multiple proinflammatory cytokines are released by M1-type
microglia that determine the tissue damage. Here, we review the
most important cytokines released from the M1- type
of microglia.
Tumor Necrosis Factor
TNF is a well-known proinflammatory cytokine that mediates
tissue damage after stroke through multiple mechanisms. When
TNF was administered directly to the brain parenchyma, it elicited
local microvascular injury in the form of pericapillary edema (28)
and leukocyte adhesion to cerebral capillaries (29). Similarly, when
TNF was administered into the cerebroventricular space prior to
ischemia, it augmented the extent of tissue damage, expanded the
otherwise average infarct volume, and aggravated neurological
deficits (30). These facts highlight the pro-inflammatory potential
of TNF in brain ischemia. TNF mediates a neurodegenerative
cascade through interferon receptors (INFRs) which are present
on infiltrating macrophages, T-lymphocytes, glia, and neurons
(31). TNF modulates gene expression via simple, direct signaling
pathway resulting in secretions of pro-inflammatory mediators by
these cells (32).
TNF released by activated microglia within the ischemic area
of the brain binds to two types of receptors, namely TNF-
receptors 1 (TNFR1) and TNF-receptor 2 (TNFR2) (33). The
role of TNFR1 as well as its extended relationship with
neurodegenerative outcomes have been well established. The
activation of TNFR1 begins when the trimeric TNF binds to
the trimeric receptor complex (Figure 1) (34). This triggers a
complex formation with several adapter proteins, such as TNF-
receptor-associated death domain (TRADD) and Fas-associated
death domain (FADD). These adaptor proteins bind with the
intracellular part of TNFR1, which consists of the 80-amino acid
death domain (DD). The point at which the adaptor proteins
bind is important (35).
We refer to this as the bifurcation point, as it will decide on
the nature of signaling and further cell fate. Cell death signals will
prevail if binding adapter proteins are Fas-associated protein and
caspase-8 (that is probably the reason why caspase inhibitors
reduce ischemic injury) (36). On the other hand, the
inflammatory messages will be produced via expressing
relevant genes when these adapter proteins are receptor-
interacting protein kinase 1 (RIPK1) (leading to nuclear factor
kB) or c-Jun N-terminal kinase (JUN) (37, 38). Consequently,
infiltrating cells synthesize adhesion molecules and release IL-1,
nitric oxide, and plasminogen activator inhibitor-1 (39). All theseOctober 2021 | Volume 12 | Article 748663
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expanding stroke volume.
Apoptosis is a distinct form of cell death that is functionally
and morphologically different from necrosis. Nuclear chromatin
condensation, cytoplasmic shrinking, dilated endoplasmic
reticulum, and membrane blebbing characterize apoptosis
in general.
Interleukin-1b
Experimental studies show that the major form of IL-1
contributing to ischemic injury is IL-1b (40). In one study,
chronic deletion of IL-1b receptors failed to deteriorate
ischemic brain damage, employing the neurotoxic potentials of
IL-1b via their receptors (41). IL-1 proteins are thus key players
in signaling pathways such as apoptosis, toll-like receptorsFrontiers in Immunology | www.frontiersin.org 3(TLRs), mitogen-activated protein kinase (MAPK), NOD-like
receptors (NLRs), and nuclear factor k-light-chain-enhancer of
activated B Cells (NF-kB) (32).
The IL-1 family consists of eleven isoforms, out of which IL-
1a and IL-1b play a strong pro-inflammatory role in
neurodegenerative diseases (42). Another member of this
family is the endogenous IL-1 receptor antagonist (IL-1Ra). In
neurodegenerative diseases, IL-1b is considered one of the main
culprits for infiltration of neutrophils, shattering of the BBB,
astrogliosis, and neovascularization (43, 44). Support for this
concept was obtained by employing the IL-1b antagonist on
brain tissues. This significantly limited brain lesions as well as
excitotoxic damage in rats (45).
IL-1 produced by neurovascular endothelial cells, resident
microglia, astrocytes, and infiltrating macrophages binds to IL-1FIGURE 1 | Post-stroke neuroinflammatory pathway of TNF. TNF released from activated microglia binds to the trimeric TNFR1, primarily present on infiltrating
leukocytes. This allows the intracellular part of the receptor to complex with the adaptor proteins TRADD and FADD via its death domain. This domain activates
cytoplasmic caspase-8 enzyme. Activated caspase-8 acts as a transcriptional factor, entering the nucleus to induce target genes. The expressed mRNA encodes
proteins such as adhesion molecules, IL-1, nitric oxide synthase (nNOS), plasminogen-activating inhibitor-1, and apoptosis-inducing factors. This ‘mix’ contributes to
the neuronal damage in ischemic tissue following stroke.October 2021 | Volume 12 | Article 748663
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brain cells except microglia (46). Described in Figure 2, IL-1b is
initially formed as a precursor protein, which is then cleaved and
activated by caspase 1, followed by its release. The mature form of
IL-1b forms a complex with transmembrane IL-1 receptor with
the help of an accessory protein called IL-1 receptor accessory
protein (IL-1RAcP) (47).The ligand-receptor complex triggers
recruitment of various cytoplasmic proteins leading to
multifarious intracellular signaling pathways guided by self-
propagating cascades, namely deacetylation, phosphorylation,
ubiquitination, methylation and palmitoylation, subsequentlyFrontiers in Immunology | www.frontiersin.org 4initiating three key neuroinflammatory mechanisms (48). The
first key mechanism is the activation of NF-kB, second, the
initiation of the c-Jun N-terminal kinases (JNKs) pathway, and
third, the triggering of the p38 mitogen-activated protein kinase
(P32 MAPKs) pathway (30, 49, 50).
In the first mechanism, NF-kB leads to the synthesis of
neurotoxic or inflammatory mediators like TNF and diverse
chemokines, collectively causing aggravated brain damage along
with astrogliosis (51). NF-kB is a protein complex that controls
gene expression in response to extracellular signals. This
complex contains five structurally similar members: p50, p52,FIGURE 2 | The neuroinflammatory cascades of IL-1b following ischemic insult. Secreted by microvascular endothelial cells, resident microglia, astrocytes, and
infiltrating macrophages, IL-1b forms a complex with IL-1R1, aided by IL-1RAcP. This ligand-receptor complex triggers three key neuroinflammatory mechanisms. In
the NF-kB pathway, ligand-receptor binding results in the cytoplasmic recruitment of three key adaptor proteins: MYD88, TOLLIP, and TRAF6. This leads to the
activation of intermediate kinases, particularly NIK, which prevent IkB from inactivating NF-kB, indirectly allowing NF-kB-dimer formation. These dimers of NF-kB
function as transcriptional factors, entering the nucleus to induce transcription of IL-1, TNF, and many other genes in various cell types. In the JNK pathway,
downstream of the “death” signal, intracellular MAPKs phosphorylate c-Jun or related proteins, which heterodimerize with Fos proteins to form the transcriptional
factor activator protein (AP-1). AP-1 regulates gene expression that mediates pro-inflammatory cellular processes, particularly proliferation and differentiation of
infiltrating immune lineage as well as apoptosis of regional neurons. In the p38 MAPK pathway, ligand binding activates intracellular MKKK3 which in turn activates
p38-MAPK, causing expression of diverse apoptotic signals, adhesion molecules for infiltration, and IL-1.October 2021 | Volume 12 | Article 748663
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induce or, rarely, repress target genes (53). Depending on the
ligand-receptor complex, various adaptor proteins are recruited
and determine which type of message is to be transduced. For the
activation of NF-kB, upstream signaling proteins include
myeloid differentiation primary response 88 (MYD88), toll
interacting protein (TOLLIP), and tumor necrosis factor
receptor-associated factor 6 (TRAF6) (54). The recruitment
cascade ultimately leads to activation of intermediate kinases such
as interleukin-1 receptor-associated kinase (IRAK), receptor-
interacting proteins (RIP), and NF-kB inducing kinase (NIK) (55,
56). Inanormalbiological state these intermediatekinases activate a
biological complex called inhibitor of kappa B (IkB) (57), which
inactivates NF-kB in cytoplasm to prevent gene expression.
However, in a diseased or stress state (stroke), these IkB are
phosphorylated, ubiquitinated, and then degraded. In the absence
of IkBs, NF-kB subunits dimerize (e.g., p50 and p65) (49). The
dimers translocate to the nucleus as a transcriptional complex.
In the second mechanism, the ligand-receptor complex
activates c-Jun N-terminal kinases (JNKs) which exert the
“death” signaling (58). The JNKs (JNK1 and JNK3) belong to
the family of mitogen-activated protein kinases (MAPKs) that
phosphorylate several proteins including the intracellular c-Jun
protein which further heterodimerizes with Fos proteins (59).
The complex of c-Jun and Fos protein is called transcriptional
factor activator protein (AP-1) that regulates gene expression for
pro-inflammatory cellular processes including proliferation and
differentiation of infiltrating immune lineage as well as apoptosis
of regional neurons (60–62).
In the third mechanism, the ligand-receptor complex
activates mitogen-activated kinase kinase kinase-3 (MKKK3)
which in turn activates p38-MAPK (63, 64).
The three transcription factors NF-kB, AP-1, and p38-MAPK
help in modulating the gene expression for the desired biological
response in the neuronal environment. The final outcomes of these
expressions are manifested in the form of more inflammatory
damage in the brain.
The intracellular and subcellular changes stimulate the
expression of genes, which become key pro-inflammatory
mechanisms. The JUN and p38 MAPK pathways, in parallel,
induce the expression of genes for IL-6, IL-8, PCP1, COX-2, IL-
1b, and MKP-1 (60).
The more IL-1b is expressed and released, the more other
pro-inflammatory mechanisms will be activated.
Interferon Gamma
Apart from a variety of influential biological functions, IFN-g
(sourced by resident astrocytes as well as infiltrating T
lymphocytes) up regulates the expression of class II major
histocompatibility complex (MHC) molecules on the surface of
macrophages and otherT cells in brain tissues, which find their way
through the disrupted BBB (65, 66). Immunohistochemistry and
flow cytometric data show that activated CD4+ cells are found in
andaround the ischemic sitewith abundantMHCclass IImolecules
on their surface for an effective inflammatory response (67, 68).
Conversely, IFN-g not only helps polarization of other distantFrontiers in Immunology | www.frontiersin.org 5microglial cells, but also influences the differentiation of CD4+,
which further produces pro-inflammatory cytokines like IL-2, IFN-
g, and TNF (69, 70). Direct injection of IFN-g into the rat CNS
induced inflammation and cellular infiltration similar to that
observed in chronic neurological diseases (71). This was indirectly
evaluated by injecting IFN-g in IFNGR-deficient mice (72). The
results signified a lack of integrity and preservation of BBB.
In another mechanism, IFN-g up-regulates the expression of
IFN-a in microglial cells around the ischemic core, suppressing
the neuroprotective role of microglia (73).
IFN-g in the CNS facilitates helper T cell infiltration and
neuroinflammation by inducing expression of vascular cell
adhesion molecule 1 (VCAM-1), intercellular adhesion molecule
1 (ICAM-1), the chemokinesCCL2 (recruitsmonocytes,memoryT
cells, and dendritic cells to the infarct area), CXCL9 (chemokine
ligand 9 belonging to CXC chemokine family and induces
chemotaxis, promotes differentiation and proliferation of
leukocytes, and causes brain edema), and CXCL10 (secreted by
infiltrating monocytes and endothelial cells in response to IFN-g)
(74–79).
Adding to the damage, IFN-g increases the expression of MHC
class II and co-stimulatory molecules on microglial cells
(particularly M1 subtype), helping them act as antigen-presenting
cells (APCs) for infiltrating myelin-specific T cells and leading to
inflammation and demyelination (80, 81). One important thing to
highlight here is the fact that increased concentrations of IFN-g
impairs the neuroprotective potential of M2 polarized microglial
cells in severe inflammatory brain diseases (82).
By another mechanism, IFN-g binds to INFRs located on
neurovascular endothelial cells and immune cells to upregulate
the expression of transmembrane intracellular adenosine
molecule type-1(ICAM-1), resulting in infiltration of immune
cells through the compromised BBB. IFN-g also induces the gene
expression of the vascular cell adhesion molecule (VCAM-1) on
primary astrocytes, thereby further enhancing their role in
inflammation (83, 84).
IFN-g acts by binding and signaling via interferon gamma
receptors (INFGR), which are overly expressed during
inflammatory conditions in the brain (Figure 3) (85). IFNGR1 and
INFGR2consist of twodifferentprotein subunits (86). Both receptors
are not in proximity to each other until IFN-g binds to the
extracellular domain of INFGR1 and triggers the cascade (87).
Inside the cell, each subunit of IFNGR1 and INFGR2 is attached to
a unique member of the Janus family kinase family (Jaks), i.e., Jak1
and Jak2, respectively (88).As soonas IFN-gbinds to the extracellular
domain of IFNGR1, it brings IFNGR1 and INFGR2 in close
proximity, clearing the way for the point where IFN-g binds with
IFNGR1 and INFGR2. Subsequently, Jak1 and Jak2 phosphorylate
each other on each receptor domain. Phosphorylated sites become
docking points for an intracellular transducer and activator of
transcription (STATs). This will result in phosphorylation of
STATs by respective JAKs. The activated STAT1 dissociates and
forms a homodimeric complex and travels to the nucleus where it
binds to its genes to induce transcription (89, 90).
By such signaling, IFN-g participates in modulating gene
expression in microglia and astrocytes (91). Elevated levels ofOctober 2021 | Volume 12 | Article 748663
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the surface of these cells transform the pathophysiological
environment suitable for infiltration of leukocytes, release of
inflammatory cytokines, and enlargement of stroke lesions (92).
Despite various new studies exploring interactive effects of
IFN-g, it is becoming evident that this cytokine not only has
protective effects but also well proven proinflammatory and
deleterious consequences in the brain (89, 93).
Interleukin 6
A major proinflammatory cytokine which is implicated in the
expansion of ischemic volume is interleukin 6 (IL-6) (94). Diverse
stroke studies underscored the significant increase in the levels ofFrontiers in Immunology | www.frontiersin.org 6IL-6 immediately after stroke onset (95, 96). Many of these studies
implicate IL-6 as a key contributing factor in the pathogenesis of
ischemic stroke, however, some of the research studies faintly
underscore the contrary. Taking the convincing evidence, IL-6 is
being discussed here as a neuroinflammatory protein.
Resident microglia, endothelial cells of the cerebral circulatory
system, and infiltrating macrophages and T cells are fundamental
sources of its release (97–99). It acts as amessenger protein between
leukocytes, endothelial cells, and parenchymal cells (100). The
pathophysiological manifestations produced in response to IL-6-
related signaling mechanisms are multifaceted and complex.
However, various studies have pointed to some key effects of IL-6:
proliferation of infiltrating immune cells, expression of genesFIGURE 3 | The neuroinflammatory cascades of INF-g following ischemic insult. Resident astrocytes as well as infiltrating T lymphocytes are the key sources of INF-
g. Following release, INF-g binds to transmembrane INFGR, which is further composed of two subunits, INFG1 and INFG2. Each receptor subunit of INFGR is further
composed of two different proteins, with each bound to Jak1 and Jak2 respectively. INF-g binding with INFG1 part brings INFG2 in to proximity with INFG1 in such a
way that, intracellularly, Jak1 and Jak2 phosphorylate each other’s two receptor domains. These receptor domains now act as docking points for STATs to bind
with respective JAKs. The activated STAT dissociates and forms a homodimeric complex functioning as a transcription factor inducing the expression of variety of
protein signals in various cell types. In cerebral ischemia, upregulated proteins are adhesion molecules on a variety of cells that play their role in the disruption of the
BBB and the infiltration of leukocytes, along with proliferation of pro-inflammatory cells.October 2021 | Volume 12 | Article 748663
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endogenous secretions (28, 101, 102). These conclusively add
more to the neuroinflammation and its deteriorating effects.
IL-6 signaling transduction is mediated by the IL-6 receptor
(IL-6R) found on a limited subset of immune cells in the brain
including microglia, endothelial cells, and infiltrating T cells (not
on oligodendrocytes and astrocytes) (103). The IL-6 receptor is
activated via two separate, but related, pathways (Figure 4), the
classical and the trans-signaling pathways (104).Frontiers in Immunology | www.frontiersin.org 7The classical pathway (producing neuroprotective outcomes)
begins when IL-6 binds with membrane bound IL-6R. The
membrane-bound IL-6R is composed of two subunits: the IL-6R-
a chain (to which IL-6 binds) and the assisting transmembrane
signaling subunit, glycoprotein 130 (gp130), which is the intra-
cellular signal transducer and abundantly expressed during
ischemic stroke (105, 106). This gp130-associated signaling
utilizes intracellular JAK/STAT signaling pathways (107). In this
pathway, the complex of IL-6, IL-6R-a, and gp130 results inFIGURE 4 | Neuroinflammation downstream of IL-6 in stroke. IL-6 binds its receptor and proceeds two separate but related pathways: the classical and trans-
signaling pathways. The classical pathway begins when IL-6 binds with IL-6R-a chain subunit assisted by gp130, an intra-cellular signal transducer. This binding
allows intracellular, receptor-associated JAKs to phosphorylate each other on respective tyrosine domains. Phosphorylated JAKs further phosphorylate related
tyrosine residues on the receptor, creating binding sites for proteins possessing SH2 domains. Cytoplasmic STATs then bind to these SH2 domains to be
phosphorylated by respective JAKs, making them dissociate from the receptor. The dissociated STATs form dimers, which act as transcription factors. The dimers
translocate to the cell nucleus to induce gene expression for subsequent protein signaling outcomes. STATs may also be tyrosine-phosphorylated directly by
receptor tyrosine kinases - but since most receptors lack built-in kinase activity, JAKs are usually required for signaling. The trans-signaling pathway begins when IL-
6 ligands with sIL-6R-a in the extracellular matrix. The high affinity drives this complex to bind with gp130 expressed overly on glial and neuronal cells following
ischemic insult. This trio-binding results in the activation of intracellular tyrosine-associated JAKs. Phosphorylated tyrosine-sited allow the adaptor proteins (SoS and
Grb-2) to bind and convert inactive cytoplasmic RAS to an active one, initiating a series of phosphorylations of a variety of molecules like Raf, MEK, and ERK. The
activated ERK acts as a transcriptional factor. It enters the nucleus to express targeted genes for inflammatory protein signaling.October 2021 | Volume 12 | Article 748663
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receptor domain) into close proximity. Each JAK is phosphorylated
by the other on a respective tyrosine domain. The activated JAKs in
turn phosphorylate related tyrosine residues on the receptor,
creating binding sites for proteins possessing SH2 domains (5).
STATs bind to the phosphorylated tyrosines on the receptor using
their SH2 domains, and are then tyrosine-phosphorylated by JAKs,
causing the STATs to dissociate from the receptor (2). These
activated STATs form hetero- or homodimers, where the SH2
domain of each STAT binds the phosphorylated tyrosine of the
opposite STAT, and the dimer then translocates to the cell nucleus
to induce transcription of target genes (2). STATs may also be
tyrosine- phosphorylated directly by receptor tyrosine kinases;
however, since most receptors lack built-in kinase activity, JAKs
are usually required for signaling.
In trans-signaling pathway (promote inflammatory outcomes),
many cell types in the brain respond to released IL-6 by releasing a
soluble form of IL-6R-a (sIL-6R-a) in the extracellular
environment. Enzymes cut free the sIL-6R-a at the basepoint
near the cell membrane (108–110).. This cleavage is done by
metalloproteases including A Disintegrin And Metalloproteinase
(ADAM) family members ADAM10 and ADAM17 (111).
Shedding of the sIL-6R-a allows the free receptor to bind with IL-
6 ligand in the extracellularmatrix. This sIL-6R-a and IL-6complex
has a very high affinity to membrane bound gp130 (present on the
cell membrane of distant glial and neuronal cells), causing
activation of intracellular tyrosin-kinases, such as Janus kinase
(JAK), which in-turn activates two pathways: activation of JAK-
STAT pathway (upregulate the synthesis of iNOS, T cell
differentiation)and the RAS-RAF-MAPK pathway (112–114).
Both these mechanisms lead to expression of genes which are
associated with producing inflammatory outcomes (115). IL-6
also induces excess production of vascular endothelial growth
factor (VEGF), leading to enhanced vascular permeability, which
is one of the many pathological features of inflammatory lesions
in the brain (116).ROS BURST IN NEUROINFLAMMATORY
TRIANGLE
Reactive oxygen species (ROS) are a group of reactive oxygen-
containing molecules including superoxide, peroxides, single
oxygen, and hydroxyl radical (117, 118). ROS perform
significant physiological roles in diverse biological processes
such as intracellular signaling, regulation of transcription,
immune response modulation, and apoptosis (119–122).
Under normal physiological conditions in the brain, ROS are
produced through two pathways: enzymatic and non-enzymatic
pathways (123). Enzymatic pathway is undertaken intracellularly
by endogenous enzymes, while non-enzymatic pathway is
carried out via antioxidative mechanisms (124, 125). Brain
cells entail enzymes such as superoxide dismutase (SOD),
glutathione peroxidase (GPX), and catalases (CAT) (126). SOD
primarily dismutases superoxide to hydrogen peroxide which is
further broken down into water and oxygen by GPX and CATFrontiers in Immunology | www.frontiersin.org 8(127). In the second pathway, ROS level in the extracellular
environment is regulated exclusively by small antioxidant
molecules which can be water-soluble or lipid-soluble (128).
These antioxidant molecules include Vitamin C, Vitamin E and
glutathione, N-acetylcysteine, and melatonin (129, 130).
Normally, equation of ROS generation is balanced by the
neutralization of ROS by antioxidants (131). Functional roles
of ROS at cellular and subcellular levels are unique and diverse.
ROS are central to apoptosis, which in turn is key tomaintaining
cellular homeostasis like synaptic activity, maintenance of vascular
tone, and mediation of inflammatory response (132–134).
Apoptotic signaling is translated by ROS through the activation
of c-JunN-terminal kinases and activation of death receptors (135).
Similarly, immune cells (microglia and infiltratingmacrophages) in
the brain are only able to completely digest the engulfed microbes
through intracellular oxidative burst (121, 136). Also, a variety of
cellular signaling in the brain requires ROS for the activation of
transcriptional factors like p53 andNF-kB for functional outcomes.
ROS have a central role to play as secondmessengers for epidermal
growth factor, platelet-derived growth factor (137), and substance P
receptor (138–141).
In the post-stroke phase, the damaged neurons give rise to
ROS burst when anti-oxidants fail to maintain this equation
resulting in excessive oxidative stress (121). Resultantly, a series
of chemical reactions begin where ROS reacts with cellular
components of brain cells (142). The more brain cells die, the
more the neuroinflammatory effects are.
In a stroke episode, ROS burst causes generalized protein
oxidation by disrupting peptide bonds in the amino acid chain,
resulting in cross-linkage and denaturation of proteins (Figure 5)
(143). Structural alteration in protein molecules causes enzyme
inactivation (119) and ion-channel dysfunction (144). One study
has demonstrated how protein oxidation causes neurotoxicity by
triggering denaturation of glutamine synthetase in mice. In
astrocytes, glutamine synthetase transform glutamate to
glutamine to protect the neuronal construct against excitotoxicity
(145). However, following ischemic stroke, denaturation of various
cerebral enzymes fans neuroinflammatory outcomes (27). Lipid
peroxidation is another feature of ROS in brain tissues (146).
The phospholipid cell membrane of brain cells is concentrated
with fatty acids, particularly polyunsaturated fatty acids. Lipid
structures have carbon-carbon double bonds (C=C) which are the
target sites for ROS (147). ROS interaction with C=C in lipid
molecules produces lipid radicals which further interact with
oxygen to make lipid peroxyl radical (148).This lipid peroxyl
radical reacts with another proximally available lipid acid to
synthesize lipid radical and lipid peroxide (149). These two lipid
radicals give rise to highly reactive malondialdehyde (MDA) and
(150) (4-HNE), the end products and markers of lipid peroxidation
(151). MDA and 4-HNE have devastating effects on neighboring
neuronal and non-neuronal cells (152). MDA reacts with enzymatic
proteins to form advanced end-products of lipid peroxidation,
further contributing secondary deleterious effects in
neuroinflammation (153). Parallel to this, 4-HNE chemically reacts
with hydroxyl group, aldehyde, and C=C in various biological
molecular structures to paralyze them functionally (150). It has aOctober 2021 | Volume 12 | Article 748663
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as a second messenger in the regulation of various transcriptional
factors such as erythroid 2-related factor 2, activating protein-1, NF-
kB, and peroxisome-proliferator-activated receptors (154). Various
studies have also highlighted the influential role of 4-HNE inMAPK
and PI3K/AKT pathways to produce damaging effects following
ischemic stroke (155). In one study, vitamin E has demonstrated
reduced lesion volume and diminished behavioral impairments in
animal MCAOmodels (156). Also, EPC-K1, a Vitamin C analogue,
reduced lesion size in ratMCAOmodel by limiting lipidperoxidationFrontiers in Immunology | www.frontiersin.org 9(157).Mitochondrial respiratory burst is anothermajor contributory
factor in neuronal cell death following stroke, saliently explained in
Figure 6 here.
Increased concentration of 8-hydroxy-2’-deoxyguanosine
(8OHdG) is a fundamental marker used by various studies
suggesting oxidative DNA damage (158). In the ischemic brain,
DNA oxidation suggests DNA disintegration, crosslinking of DNA
with denatured protein molecules, as well as DNAmutation (159).
Oxidative stress significantly contributes to the detrimental
effects of neuroinflammation. Various antioxidant therapeuticFIGURE 5 | The ROS burst following ischemic insult and damage to biological molecules. Following hypoxia, brain cells witness a swift imbalance between ROS
production and their neutralization mechanisms, particularly in neuronal cells, resulting in a constant rise in ROS levels, called ROS burst. One of the key sources of
ROS burst inside the cell is mitochondria, others being cell membrane and peroxisomes. These ROS molecules damage cellular parts via protein oxidation, lipid
peroxidation, and DNA damage. The neuronal nitric oxide synthase (nNOS) in the cytoplasm of hypoxic neuron produces excessive production of Nitric Oxide (NO)
which after release reacts with cellular oxygen producing peroxinitrite (ONOO⁻), a powerful oxidant damaging cytoplasmic proteins and lipid composites. Another
ROS-releasing source during hypoxia is the extracellular space-facing membrane bound enzyme called NADH oxidase. This enzyme releases ample quantities of
superoxide molecules with respective damaging implications. A third major source of ROS release is the mitochondria. The external membrane-bound monoamine
oxidase (MAO) releases a range of reactive molecules, primarily H2O2, which causes the production of hydroxyl radical (HO•) and hydroperoxyl radical (HO2⁻). These
two radicals cause lipid peroxidation by selectively attacking carbon-carbon double bond (c=c) of saturated lipid compounds, releasing by-products such as 4-
Hydroxynonenal (4-HNE), Hexanol, Propanol, and Malondialdehyde. Of these, the latter is a highly reactive organic compound, aggressively reacting nucleic material
to cause DNA fragmentation. The key DNA fragmentation marker of this pathway is 8-Hydroxydeoxyguanosine (80HdG). The hypoxia-induced impaired
mitochondrial functions, especially affected Complex I, III, and IV, which drive Electron Transport Chain (ETC), release abundant quantities of Superoxides (O2•⁻) into
the cytoplasm. These superoxides further produce reactive species which have two-fold damaging effects. On the one hand, these inactivate chaperones result in
increased levels of misfolded proteins and, on the other hand, cause carbonylation of cellular proteins. This carbonylation of proteins is evident by the elevated levels
of carbonylation marker in stroke, such as 4-Hydroxy, 4-oxoneonenal.October 2021 | Volume 12 | Article 748663
Shaheryar et al. Neuroinflammatory Mechanisms in Strokeapproaches, i.e. polyethylene glycol-conjugated SOD (PEG-
SOD) (160) and polyethylene glycol-conjugated CAT (PEG-
CAT) (161), underscore that timely interventions following
stroke attenuate neuroinflammatory damage partially due to
limiting the ROS generation (162).BLOOD-BRAIN BARRIER IN
NEUROINFLAMMATORY TRIANGLE
The integrity of neurovascular structure is crucial to maintaining
a neurophysiological barrier against movement of ions,
molecules, systemic immune cells, and subcellular components
(163). This barrier is called the Blood Brain Barrier (BBB) and isFrontiers in Immunology | www.frontiersin.org 10composed of four key components: brain microvascular
endothelial cells (BMEC), Astrocytes, Pericytes, and Microglial
cells (164).
BMEC have contrasting features to systemic endothelial cells
with closely-fitted junctions to give high ionic transportation,
paracellular flux, presence of disproportionately distribution of
enzymes, and hermetically sealed carrier-mediated transport
system (165). A variety of biological compounds (from glucose
to amino acids, and from exogenous drugs to minerals) enter the
brain tissue via a special carrier-protein system which is
abundantly expressed in BMECs (166). Apart from expressing
brain-derived neurotrophic factor (BDNF), transferrin receptor
proteins, insulin receptors, and insulin-like growth factor
receptor, BMECs also express powerful vasoactive endothelin-1FIGURE 6 | Intrinsic apoptotic signaling and resultant neuronal death driven by ischemic-induced ROS burst. Ischemic events cause mitochondrial matrix of the
neurons uptake extracellular calcium as a result of augmented mitochondrial respiratory burst. This calcium accumulation not only causes inactivation of anti-
apoptotic proteins (BCL-2 and BCL-x) inside mitochondria but also results in an increase in the permeability of the outer and inner mitochondrial membranes. This
permeation allows cytoplasmic Bax proteins to enter and make ‘tunnel-like’ complexes with mitochondrial Bar proteins, which then embed into the outer
mitochondrial membrane as Bax-Bar pores. These specialized pores serve as channels to transport intra-mitochondrial pro-apoptotic proteins (AIF, Cy A, APAF-1,
and Cyt C) into the cytoplasm. The AIF and Cy A make a complex (AIF-Cy A complex), directly entering the nucleus to inflict defragmentation. Similarly, APAF-1
binds with Cyt C to transform pro-Caspase 8 protein into an active form: Caspase 8. The Caspase 8 enters through the nuclear pores to activate Caspase Activated
DNase (CAD) which defragments the nuclear material, a key apoptotic signaling outcome. This dual apoptotic signaling effect is primarily initiated by a respiratory
burst in the affected neuron following ischemic insult.October 2021 | Volume 12 | Article 748663
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vasodilatory nitric oxide (NO) (167–171).
A balance between ET-1 and NO is crucial for ensuring normal
homeostasis in the brain (172). A sudden change in this balance
(ischemic stroke) inflicts pathophysiological devastation (173).
Expression of ET-1increases in response to ROS burst, neuronal
damage, inflammatory cytokines, and thrombin (174).Within a
day, the level ofET-1 inCerebrospinal Fluid (CSF) rises significantly
due to astrocytes and endothelial cells which bind numerously
expressed ET-1 receptors localized on neurons, glial cells,
microvascular endothelial, and smooth muscle cells to give rise to
assorted paracrine physiological effects (175–179).
Firstly, ET-1 upsurges the expression of a variety of adhesion
molecules from BMECs such as intercellular adhesion molecule 1Frontiers in Immunology | www.frontiersin.org 11(ICAM-1; CD54) (180), vascular cell adhesion molecule-1
(VCAM-1; CD106) (181), and endothelial-leukocyte adhesion
molecule 1 (ELAM-1; CD62) (182, 183).
Secondly, ET-1 activates meningeal Mast Cells (MCs) which,
upon degranulation, release inflammatory cytokines, playing a
contributory role in disrupting BBB (184).
Thirdly, being a powerful vasoconstrictor, it induces long-
term blood flow occlusion to the area affected by ischemic insult,
thus further fanning neuronal damage, ROS production, and
cytokine release (185).
Contrary to this, NO is a minor biological radical which is
produced by nitric oxide synthase (NOS) enzyme family from L-
arginine (186). NOS have three discrete anatomical sources:
neuronal NOS (nNOS), inducible NOS(iNOS), and endothelialFIGURE 7 | Ischemic stroke and orderly compromisation of BBB. The brain microvascular endothelial cells (BMECs), Astrocytes, Pericytes, and Microglial cells make
BBB. Compromised BBB integrity is the striking preliminary feature of the neuroinflammatory-triangle during the hypoxic pathophysiological state, where astrocytes in
penumbra, pericytes, and BMECs start releasing ET-1 (disturbed balance of ET-1 and NO). This leads to the upsurge in the expression of a variety of adhesion
molecules in/on BMECs such as ICAM-1, VCAM-1, and ELAM-1 to facilitate trans-endothelial migration of leukocytes. ET-1 also upregulates the expression and
release of matrix metalloproteinases (MMP) from BMECs which lyse inter-endothelial connecting proteins such as Claudin 1, Claudin 5, Ocludin, Zona ocludin-1,
junctional adhesion molecule-A (JAM-A), and others. This compromises the barrier’s integrity, otherwise tightly maintained by BMECs, thus allowing the release of
inflammatory cytokines, infiltration of systemic immune cells, and fluid escape (brain edema). Inflammatory cytokines stimulate meningeal Mast Cells to release more
inflammatory mediators to further the BBB shattering and causing long-term occlusion of blood to already starved brain tissue. Along with BMECs, the functionally
compromised Pericytes and Astrocytes in penumbra put their respective neurodegenerative part (crossed red-mark in dotted boxes). The population of infiltrating
immune cells and their pro-inflammatory secretions proceeds a vicious neuroinflammatory circle that only aggravates brain edema and infarct volume.October 2021 | Volume 12 | Article 748663
Shaheryar et al. Neuroinflammatory Mechanisms in StrokeNOS (eNOS) (187–189). Of these, eNOS have a regulatory role in
BMECs (190). Normally, eNOS triggers vasodilation, inhibits
platelet aggregation, and revitalizes blood flow to brain tissues; in
short, they provide neuroprotective effects (191). This is the
other way round in neuroinflammatory cascade where excessive
ET-1 production suppresses eNOS expression and further
microvascular contraction hinders blood supply to the
ischemic site (192).
In this hyper-inflammatory state, BMECs also synthesize
enhanced matrix metalloprotein-2 (MMP-2) in response to
inflammatory signals (Figure 7) (193) which digest proteins
(claudin-1, claudin-5, occludin, and zonula occludens-1) (194)
responsible for maintaining tight junctions between endothelial
cells, further compromising the BBB integrity (195).
An additional key component of the BBB is astrocyte, which
has an inverse relation with neuroinflammatory damage.
Following ischemic damage, astrocytes offer recovery back into
neurons because they are more resistant to glucose-oxygen
deprivation mechanisms (196). Astrocytes release glutathione
and SOD in response to ROS burst to reduce oxidative damage
and neuronal mortality (197). Apart from this, they enhance
potassium uptake to prevent excitotoxicity of neurons following
post-stroke extracellular surge in the potassium levels (198).
Also, astrocytes overly express glucose transporters to keep the
supply of glucose to energy- stressed/dying neurons (199). This is
evident by various studies which have found high levels of
neuroprotective ethyl pyruvate (a derivative of the energy
substrate pyruvate) only when astrocytes proximal to stroked
area remain functional (200).
However, impaired astrocytes amplify neuronal damage
(201). A miscalculated interactive cascade of ROS, increased
pro-inflammatory cytokine production, and downregulation of
anti-inflammatory cytokines along with disrupted BBB play
decisive roles in astrocyte functions (202–204). The third
component of BBB is pericytes which have multifaceted roles
in the brain following ischemic injury.
Brain injury causes increased expression of adhesion
molecules (ICAM-1 and VCAM-1) on pericytes in response to
inflammatory cytokines (205, 206). In addition to this, various
other molecules are overly expressed on pericytes including a-
smooth muscle actin, Platelet-derived growth factor subunit B
(PDGF-b), transforming growth factor-b (TGF-b), and
andangiopoieten-1 (207–210). Pericytes have a constructive
function against inflammatory responses, of these some include
contractile maneuvers with endothelial smooth muscles,
immune and phagocytic roles, migration to endothelial cells toFrontiers in Immunology | www.frontiersin.org 12provide supportive functions, angiogenic support, and stem cell
functions (211–216). However, once the BBB losses integrity as a
result of neuroinflammatory chain reaction, these supportive and
angiogenic functions of astrocytes are compromised severely
(217). The fourth component of the BBB, i.e., microglial cells,
has been elaborated on above.CONCLUSIONS
Non-availability of clinically reliable therapeutic interventions for
limiting stroke-related morbidities and mortalities puts the
significance of clinical trials into question. This suggests that such
efforts are not specifically targeted enough or that the targeted
mechanisms differed between species, as most of the mechanistic
studies are carried out in small animal models of stroke.
Contemporary trends in stroke studies are heading towards
unearthing intricate intracellular signaling pathways which are
involved in neuroinflammation and stroke damage. Establishing a
significant link between these pathways can only help explore
potential targets for finding therapeutic interventions. The
neuroinflammatory triangle entails diverse links which are central
to stroke-related damage. Further reconnoitering this
neuroinflammatory triangle might be rewarding and aid in
finding and clinically translating novel therapeutic targets.AUTHOR CONTRIBUTIONS
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Course of Oxidative Damage in Different Brain Regions Following Transient
Cerebral Ischemia in Gerbils. Neurosci Res (2001) 41(3):233–41. doi:
10.1016/S0168-0102(01)00282-6
152. Adibhatla RM, Hatcher J, Dempsey R. Lipids and Lipidomics in Brain Injury
and Diseases. AAPS J (2006) 8(2):E314–21. doi: 10.1007/BF02854902Frontiers in Immunology | www.frontiersin.org 16153. Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence That
Amyloid Beta-Peptide-Induced Lipid Peroxidation and Its Sequelae in
Alzheimer’s Disease Brain Contribute to Neuronal Death. Neurobiol Aging
(2002) 23(5):655–64. doi: 10.1016/S0197-4580(01)00340-2
154. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial ROS-Induced ROS
Release: An Update and Review. Biochim Biophys Acta (BBA) Bioenergetics
(2006) 1757(5-6):509–17. doi: 10.1016/j.bbabio.2006.04.029
155. Pradeep H, Diya JB, Shashikumar S, Rajanikant GK. Oxidative Stress–
Assassin Behind the Ischemic Stroke. Folia Neuropathol (2012) 50(3):219–
30. doi: 10.5114/fn.2012.30522
156. Gariballa S, Hutchin T, Sinclair A. Antioxidant Capacity After Acute
Ischaemic Stroke. Qjm (2002) 95(10):685–90. doi: 10.1093/qjmed/95.10.685
157. Zhang W, Hayashi T, Sasaki C, Sato K, Nagano I, Manabe Y, et al.
Attenuation of Oxidative DNA Damage With a Novel Antioxidant EPC-K1
in Rat Brain Neuronal Cells After TransientMiddle Cerebral Artery Occlusion.
Neurol Res (2001) 23(6):676–80. doi: 10.1179/016164101101199027
158. Kumar L, Kumar S, Agarwal S. To Find the Role of DNA Damage Marker 8-
Hydroxy 2-Deoxy Guanosine in Patients of Prostate Cancer, Benign
Prostatic Hyperplasia and Its Association to Other Prognostic Factors of
Prostate Cancer. J Integr Nephrol Androl (2017) 4(2):55. doi: 10.4103/
jina.jina_5_17
159. Hwang IK, Yoo K-Y, Kim DS, Jeong Y-K, Dai Kim J, Shin H-K, et al.
Neuroprotective Effects of Grape Seed Extract on Neuronal Injury by
Inhibiting DNA Damage in the Gerbil Hippocampus After Transient
Forebrain Ischemia. Life Sci (2004) 75(16):1989–2001. doi: 10.1016/
j.lfs.2004.05.013
160. Cho H-J, Yoon I-S, Yoon HY, Koo H, Jin Y-J, Ko S-H, et al. Polyethylene
Glycol-Conjugated Hyaluronic Acid-Ceramide Self-Assembled
Nanoparticles for Targeted Delivery of Doxorubicin. Biomaterials (2012)
33(4):1190–200. doi: 10.1016/j.biomaterials.2011.10.064
161. Hernandes MS, Britto LRG, Real CC, Martins D, Lopes LR. Reactive Oxygen
Species and the Structural Remodeling of the Visual System After Ocular
Enucleation. Neuroscience (2010) 170(4):1249–60. doi: 10.1016/
j.neuroscience.2010.07.065
162. Shirley R, Ord EN, Work LM. Oxidative Stress and the Use of Antioxidants
in Stroke. Antioxidants (2014) 3(3):472–501. doi: 10.3390/antiox3030472
163. Del Zoppo G. The Neurovascular Unit in the Setting of Stroke. J Internal
Med (2010) 267(2):156–71. doi: 10.1111/j.1365-2796.2009.02199.x
164. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood–brain Barrier:
Structural Components and Function Under Physiologic and Pathologic
Conditions. J Neuroimmune Pharmacol (2006) 1(3):223–36. doi: 10.1007/
s11481-006-9025-3
165. Lee T-H, Avraham H, Lee S-H, Avraham S. Vascular Endothelial Growth
Factor Modulates Neutrophil Transendothelial Migration via Up-Regulation
of Interleukin-8 in Human Brain Microvascular Endothelial Cells. J Biol
Chem (2002) 277(12):10445–51. doi: 10.1074/jbc.M107348200
166. Michiels C. Endothelial Cell Functions. J Cell Physiol (2003) 196(3):430–43.
doi: 10.1002/jcp.10333
167. Ramos-Cejudo J, Gutiérrez-Fernández M, Otero-Ortega L, Rodrıǵuez-Frutos
B, Fuentes B, Vallejo-Cremades MT, et al. Brain-Derived Neurotrophic
Factor Administration Mediated Oligodendrocyte Differentiation and
Myelin Formation in Subcortical Ischemic Stroke. Stroke (2015) 46
(1):221–8. doi: 10.1161/STROKEAHA.114.006692
168. Gosk S, Vermehren C, Storm G, Moos T. Targeting Anti—Transferrin
Receptor Antibody (OX26) and OX26-Conjugated Liposomes to Brain
Capillary Endothelial Cells Using In Situ Perfusion. J Cereb Blood Flow
Metab (2004) 24(11):1193–204. doi: 10.1097/01.WCB.0000135592.28823.47
169. Bondy CA, Cheng CM. Signaling by Insulin-Like Growth Factor 1 in Brain.
Eur J Pharmacol (2004) 490(1-3):25–31. doi: 10.1016/j.ejphar.2004.02.042
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